GSK Gears Up for Q1 Earnings: Here's What to Expect
- We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
- 04/23/2024
|
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
- ADHERE data show VYVGART ® Hytrulo has potential to be first advancement for CIDP patients in 30 years
- 04/16/2024
|
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease
- RHO study supports proof-of-concept in primary Sjogren's disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its plan to continue the development of efgartigimod to Phase 3 in adults with primary Sjogren's disease (SjD), following the analysis of topline data from the Phase 2 RHO study. Detailed results will be presented at a future medical meeting.
- 03/27/2024
|
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
- March 26, 2024 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Tuesday, May 7, 2024 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands. The shareholders and all other persons with meeting rights are invited to attend the Annual General Meeting of shareholders.
- 03/26/2024
|
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
- VYVGART ® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP)
- 03/26/2024
|
Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday
- Argenx (ARGX) surges after a Japanese rival posted disappointing results from a late-stage study on its investigational drug for generalized myasthenia gravis.
- 03/22/2024
|
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
- Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- 03/22/2024
|
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
- Biotech stocks Argenx and Immunovant surged Thursday — and Tourmaline fell — on a rival's lackluster muscle disease drug study.
- 03/21/2024
|
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
- ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years Abstracts reflect real-world value and consistent efficacy and safety profile associated with long-term use of VYVGART® and VYVGART® Hytrulo in gMG patients March 7, 2024, 10:01 pm CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that eight abstracts, including two oral presentations, featuring clinical trial and real-world data for VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in rare autoimmune diseases will be presented at the American Academy of Neurology (AAN) Annual Meeting, taking place in Denver, CO from April 13-18, 2024. “We are opening a new chapter for the VYVGART portfolio,” said Luc Truyen, M.D.
- 03/07/2024
|
argenx SE (ARGX) Q4 2023 Earnings Call Transcript
- argenx SE (ARGX) Q4 2023 Earnings Call Transcript
- 02/29/2024
|
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
- $374 million in fourth quarter and $1.2 billion in full year global net product sales sBLA for VYVGART® Hytrulo for CIDP accepted for priority review by FDA with PDUFA target action date of June 21, 2024 On track to report data from six Phase 2 proof-of-concept trials by end of 2024 Management to host conference call today at 2:30 pm CET (8:30 am ET) February 29, 2024, 7:00 am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported financial results for the full year 2023 and provided a fourth quarter business update. “argenx reached thousands of new patients and their families in 2023 by delivering on our commitment to make VYVGART available to the global MG community,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
- 02/29/2024
|
Is a Surprise Coming for argenx (ARGX) This Earnings Season?
- argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/28/2024
|
argenx to Present at Upcoming Investor Conferences
- February 26, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in March:
- 02/26/2024
|
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
- February 22, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 29, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2023 financial results and provide a fourth quarter business update.
- 02/22/2024
|
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
- Now that the FED is looking to lower interest rates this year, cheaper money and more accessible financing will let investors venture into riskier places in the economy and the stock market. While not that risky of an industry, the biotech space can often be speculative.
- 02/21/2024
|
5 medical stocks growing earnings by triple digits
- While most of the market focuses on hyper-growth technology stocks rewarded by Wall Street as long as they mention the word "artificial intelligence" in their earnings calls, the reality is that the fundamentals now favor other (safer) areas of the economy.
- 02/06/2024
|
argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion
- Vyvgart generated $1.2 billion in net sales in 2023 and is in a good position to continue performing well in 2024 and beyond. Empasiprubart has generated strong results in the first cohort of MMN patients, putting this candidate on investors' radars and offering something other than Vyvgart. Pipeline expansion includes ARGX-213, the next-generation Vyvgart, which could address some of Vyvgart's limitations and extend the patent life of the anti-FcRn franchise.
- 02/01/2024
|
How Argenx (ARGX) Stock Stands Out in a Strong Industry
- Argenx (ARGX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 01/12/2024
|
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 9:00 a.m. PT.
- 01/02/2024
|
5 Biotech Acquisition Targets To Accumulate In 2024
- Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions.
- 12/21/2023
|
argenx (ARGX) Tanks on Top-Line Data From Pemphigus Study
- argenx's (ARGX) phase III ADDRESS study, evaluating efgartigimod subcutaneous for treating pemphigus, fails to meet primary and secondary endpoints. Stock falls.
- 12/21/2023
|
Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off
- Immunovant unveiled promising results for a Graves' disease treatment on Thursday, helping IMVT stock reverse a recent downfall.
- 12/21/2023
|
Why Is Argenx (ARGX) Stock Down 25% Today?
- Shares of biotechnology specialist Argenx (NASDAQ: ARGX ) — which focuses on addressing severe autoimmune diseases – suffered a hefty decline on Wednesday following a clinical disappointment. Its Phase 3 study for a disease that causes skin blisters failed to meet its primary and secondary objectives.
- 12/20/2023
|
This biotech stock is down 25% on Wednesday: find out why
- Argenx SE (NASDAQ: ARGX) says a late-stage trial of its candidate drug for an autoimmune condition failed to meet the primary or secondary endpoints. Its shares are down 25% at writing.
- 12/20/2023
|
Argenx stock dives by a third after late-stage trial didn't meet goals
- Argenx stock ARGX, -33.70% ARGX, -0.64% lost a third of its value as the Amsterdam biotech said a late-stage trial did not meet primary or secondary endpoints. The Phase 3 study was of using efgartigimod subcutaneous in adults with pemphigus vulgaris and pemphigus foliaceus.
- 12/20/2023
|
These 2 Stocks Are Falling in a Fading Rally
- Stock markets looked ready to ease lower Tuesday morning after big gains earlier in the month. Zscaler stock fell back even with strong results in its fiscal first quarter.
- 11/28/2023
|
Tech Titans Rising: 7 Underrated Stocks Set for Explosive Growth
- In the world of investing, it's often the hidden gems that yield the most extraordinary returns. While Wall Street keeps a watchful eye on the giants, lesser-known stocks are quietly charting a course for explosive growth.
- 11/06/2023
|
argenx to Present at Upcoming Investor Conferences
- November 1, 2023 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in several upcoming investor conferences in November:
- 11/01/2023
|
argenx SE (ARGX) Q3 2023 Earnings Call Transcript
- argenx SE (NASDAQ:ARGX ) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Beth DelGiacco - VP and Global Head, Corporate Communications and IR Tim Van Hauwermeiren - CEO Karl Gubitz - CFO Karen Massey - COO Conference Call Participants Yatin Suneja - Guggenheim Partners Tazeen Ahmad - Bank of America Derek Archila - Wells Fargo Thomas Smith - Leerink Partners James Gordon - JPMorgan Amy Li - Jefferies Danielle Brill - Raymond James Yaron Werber - TD Cowen Myles Minter - William Blair Joel Beatty - Baird Alex Thompson - Stiefel Allison Bratzel - Piper Sandler Vikram Purohit - Morgan Stanley Manos Mastorakis - Deutsche Bank Douglas Tsao - H.C. Wainwright Joon Lee - Truist Securities Suzanne van Voorthuizen - VLK Samantha Semenkow - Citi Rajan Sharma - Goldman Sachs Charles Pitman - Barclays Operator Good morning.
- 10/31/2023
|
argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
- October 24, 2023 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Tuesday, October 31, 2023 at 1:30 pm CET (8:30 am ET) to discuss its third quarter 2023 financial results and provide a business update.
- 10/24/2023
|
argenx: Efgartigimod Is Not Just A Drug, A Cornerstone
- argenx exhibits robust financials with a Q2 YoY net sales surge to $269.3M and liquidity of $2.0B but faces increasing operating costs and R&D expenditures. Efgartigimod, ARGX's primary asset, shows high revenue potential but faces competition from IMVT-1402 and other emerging therapeutics in the autoimmune space. Investment recommendation: "Buy" with caution. Monitor the competitive landscape and consider a diversified strategy to mitigate inherent market risks.
- 10/17/2023
|
Argenx's 28% Surge & Promising Product Propel Investor Confidence
- The stock gapped up nearly 28% on July 17, after announcing better-than-expected results from a clinical trial of its treatment for patients suffering from a progressive condition that affects muscle control.
- 09/25/2023
|
This New S&P 500 Entrant Leads 5 Stocks Near Buy Points
- DraftKings and new S&P 500 entrant Airbnb lead a watch list of stocks poised to make moves if the stock market can find its footing.
- 09/16/2023
|
argenx to Present at Upcoming Investor Conferences
- August 30 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in several upcoming investor conferences in September:
- 08/30/2023
|
Is Argenx Stock a Buy Now?
- Argenx recently reported positive news from a clinical trial for its lead medicine. The company could be looking at many more approvals for this therapy.
- 07/31/2023
|
Why Shares of Argenx Jumped This Week
- Argenx has only two approved therapies, Vyvgart and Vyvgart Hytrulo. Vyvgart Hytrulo fared well in a trial to treat adults with chronic inflammatory demyelinating polyneuropathy, an autoimmune disorder.
- 07/21/2023
|
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
- July 20 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 27, 2023 at 2:30 pm CET (8:30 am ET) to discuss its half year 2023 financial results and provide a second quarter business update.
- 07/20/2023
|
argenex SE (ARGX) Surges 27.8%: Is This an Indication of Further Gains?
- argenex SE (ARGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- 07/18/2023
|
Why Argenx Stock Is on Fire Today
- Argenx's flagship autoimmune drug hit the primary endpoint in a registrational trial for a progressive nerve disorder. Investors are cheering the news today.
- 07/17/2023
|
Why Is Argenx (ARGX) Stock Up 27% Today?
- Argenx (NASDAQ: ARGX ) stock is climbing higher on Monday following the release of data from a Phase 1 clinical trial. The company released results from its ADHERE study of VYVGART Hytrulo in adults with CIDP.
- 07/17/2023
|
This Emerging Market Could Be the Next Big Thing in Biotech
- After recovering from COVID-19 infections, many people enter an extended period during which they suffer from a catalog of additional serious symptoms. It is estimated that at least 65 million people continue to experience long COVID.
- 07/14/2023
|
Halozyme: Inflection Point With argenx's Vyvgart SC Approval (Reiterating Buy)
- argenx's Vyvgart Hytrulo, a game-changer with its 1-minute SC formulation, opens a new revenue stream for Halozyme with sales expected to surpass $10Bn. Despite past headwinds, Vyvgart's SC approval and potential co-formulation patent disclosure could kick-start HALO's stock recovery. A plethora of 2023 catalysts including subcutaneous formulation data for Ocrevus and Opdivo, Tecentriq approval, and phase 3 efgartigimod CIDP readout may further elevate HALO's stock.
- 07/05/2023
|
China's NMPA approves Argenx's and Zai Lab's BLA for muscle-weakening disease treatment
- China's National Medical Products Administration (NMPA) has approved Zai Lab Limited's and Argenx SE's Biologics License Application (BLA) for VYVGART, a treatment for generalised myasthenia gravis (gMG), muscle-weakening disease, in anti-body positive adults, the Dutch company said on Friday.
- 06/30/2023
|
US FDA approves Argenx's therapy for muscle-weakening disease
- The U.S. Food and Drug Administration has approved Argenx SE's under-the-skin injection for the treatment of a muscle-weakening genetic disease called generalized myasthenia gravis, the company said on Tuesday.
- 06/20/2023
|
argenx to Present at Upcoming Investor Conferences
- May 3 1 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in two upcoming investor conferences in June:
- 05/31/2023
|
Argenx Believes It Might Have 'One Of The Biggest Biologics' Ever — And Shares Are Soaring
- Argenx could have "one of the biggest biologics of all time," the biotech company contends. Argenx stock now trades at a record high.
- 05/18/2023
|
All You Need to Know About argenex SE (ARGX) Rating Upgrade to Buy
- argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 05/09/2023
|
argenx SE (ARGX) Q1 2023 Earnings Call Transcript
- argenx SE (NASDAQ:ARGX ) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Beth DelGiacco - Vice President of Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz - Chief Financial Officer Karen Massey - Chief Operating Officer Conference Call Participants Derek Archila - Wells Fargo Tazeen Ahmad - Bank of America Rajan Sharma - Goldman Sachs Yatin Suneja - Guggenheim Akash Tewari - Jefferies Thomas Smith - SVB Security Danielle Brill - Raymond James Joel Beatty - Baird Alex Thompson - Stifel Allison Bratzel - Piper Sandler Yaron Werber - Cowen Samantha Semenkow - Citi Myles Minter - William Blair Niall Alexander - Deutsche Bank Suzanne van Voorthuizen - Kempen & Company Trevor Allred - Oppenheimer Douglas Tsao - HCW Joon Lee - Truist Securities Charles Pitman - Barclays Simon Baker - Redburn Operator Good morning. My name is Rob, and I will be your conference operator today.
- 05/06/2023
|
argenx to Present at BofA Securities 2023 Health Care Conference
- May 2 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the BofA Securities 2023 Health Care Conference on Tuesday, May 9, 2023, at 8:00 a.m. P.T. in Las Vegas, NV.
- 05/02/2023
|
argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023
- April 27 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 4, 2023 at 2:30 pm CET (8:30 am ET) to discuss its first quarter 2023 financial results and provide a business update.
- 04/27/2023
|
7 Biotech Stocks That Could Cure Your Portfolio Woes
- Fundamentally, the driving catalyst for biotech stocks to buy centers on the possibility of supporting paradigm-shifting medical breakthroughs. For example, a report published by the JAMA Network indicates that experts project the global economic cost of cancers from 2020 to 2050 will be $25.2 trillion (in constant 2017 dollar terms).
- 04/19/2023
|
These Are the Top 10 Holdings of Avoro Capital Advisors
- Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.
- 04/17/2023
|
argenx to Present at Upcoming Investor Conferences
- February 2 7 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in several upcoming investor conferences in March:
- 02/27/2023
|
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
- February 23 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, March 2, 2023 at 2:30 pm CET (8:30 am ET) to discuss its full year 2022 financial results and provide a fourth quarter business update.
- 02/23/2023
|
argenx: Priority Review Voucher Goes To Waste And Why SC Efgartigimod Is Important
- argenx pre-announced strong Q4 net sales of Vyvgart in early January. The PDUFA date for subcutaneous efgartigimod was pushed back by three months, which means the $98 million Priority Review voucher went to waste.
- 02/06/2023
|
argenex SE (ARGX) Upgraded to Buy: What Does It Mean for the Stock?
- argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 01/10/2023
|
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
- January 3 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:00 a.m. PT.
- 01/03/2023
|
100 Best Stocks Of 2022: Oil Stocks And Medicals Shine
- Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.
- 12/30/2022
|
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
- First immune thrombocytopenia (ITP) pl enary selection in 15 years underscores significant unmet need in this rare, serious autoimmune bleeding disease
- 12/10/2022
|
argenx to Present at Upcoming Investor Conferences
- November 7 , 2022 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in several upcoming investor conferences in November:
- 11/07/2022
|
argenx: Vyvgart Continues To Perform Well, Key Pipeline Catalyst Next Quarter
- Vyvgart once again exceeded sales expectations by generating $131.3 million in net sales in the third quarter. Potential approval of subcutaneous Vyvgart in 1H 2023 and geographic expansion should fuel the continued growth of Vyvgart next year.
- 10/30/2022
|
4 Biotech Stocks Set to Outpace Q3 Earnings Estimates
- Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.
- 10/21/2022
|
argenex SE (ARGX) Upgraded to Buy: Here's Why
- argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 10/20/2022
|
argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
- October 20 , 2022 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, October 27, 2022 at 2:30 pm CET (8:30 am ET) to discuss its third quarter 2022 financial results and provide a business update.
- 10/20/2022
|
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
- Here is how argenex SE (ARGX) and McKesson (MCK) have performed compared to their sector so far this year.
- 10/07/2022
|
Is Argenx (ARGX) Stock Outpacing Its Medical Peers This Year?
- Here is how argenex SE (ARGX) and Immunocore Holdings PLC Sponsored ADR (IMCR) have performed compared to their sector so far this year.
- 09/05/2022
|
argenx to Present at Wells Fargo Healthcare Conference
- August 31 , 2022 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 8:00 a.m. E.T. in Boston, MA.
- 08/31/2022
|
Here's Why argenex SE (ARGX) is a Great Momentum Stock to Buy
- Does argenex SE (ARGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 08/23/2022
|
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
- Here is how argenex SE (ARGX) and McKesson (MCK) have performed compared to their sector so far this year.
- 08/19/2022
|
argenx: Another Strong Quarter For Vyvgart
- argenx reported another strong quarter with $74.9 million in Vyvgart net sales. The company added 1,000 new patients in Q2, up from 400 in Q1.
- 08/02/2022
|
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2022 Results - Earnings Call Transcript
- argenx SE (NASDAQ:ARGX ) Q2 2022 Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Beth DelGiacco - VP Corporate Communications and IR Tim Van Hauwermeiren - CEO Karl Gubitz - CFO Keith Woods - COO Conference Call Participants Danielle Brill - Raymond James Yaron Werber - Cowen Yatin Suneja - Guggenheim Partners Derek Archila - Wells Fargo Allison Bratzel - Piper Sandler Akash Tewari - Jefferies Matthew Harrison - Morgan Stanley Tazeen Ahmad - Bank of America Securities Thomas Smith - SVB Securities Jason Butler - JMP Securities Alex Thompson - Stifel Joon Lee - Truist Securities Colin White - UBS Douglas Tsao - H. C. Wainwright Joel Beatty - Baird Manos Mastorakis - Deutsche Bank Operator Good morning.
- 07/28/2022
|
argenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022
- July 21, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 28, 2022 at 2:30 pm CET (8:30 am ET) to discuss its half year 2022 financial results and provide a second quarter business update.
- 07/21/2022
|
argenx: Biopharma Star
- 100% technical buy signals. 11 new highs and up 15.30% in the last month.
- 07/06/2022
|
argenx to Present at Upcoming Investor Conferences
- June 1 , 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in several upcoming investor conferences in June:
- 06/01/2022
|
argenx: A Very Good Start For Vyvgart
- argenx beat Q1 2022 revenue estimates thanks to a strong launch of Vyvgart in generalized myasthenia gravis. The early patient numbers look good compared to the launch of Soliris four years ago.
- 05/25/2022
|
argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term Gain
- Derivatives markets, used by the market-making community to hedge equity market liquidity trade orders, tell by their component structure and prices the subject stock's expected coming price range limits. By comparing today's balance of upside and downside price change prospects with outcome experiences of similar prior forecasts, qualitative comparisons are being made, stock by stock, of investing portfolio candidates.
- 05/18/2022
|
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q1 2022 Results - Earnings Call Transcript
- argenx SE (NASDAQ:ARGX ) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Corporate Participants Beth DelGiacco - VP Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Luc Truyen - Chief Medical Officer Karl Gubitz - Chief Financial Officer Keith Woods - Chief Operating Officer Conference Call Participants Yatin Suneja - Guggenheim Matthew Harrison - Morgan Stanley Tazeen Ahmad - Bank of America Akash Tewari - Jefferies Yaron Werber - Cowen James Gordon - JPMorgan Derek Archila - Wells Fargo Danielle Brill - Raymond James Charles Pitman - Redburn Joon Lee - Truist Securities Allison Bratzel - Piper Sandler Laura Sutcliffe - UBS Joel Beatty - Baird Douglas Tsao - H.C. Wainwright Operator Good morning.
- 05/07/2022
|
Argenx's Vyvgart Meets Primary Goal In Late-Stage Bleeding Disorder Study
- Argenx SE's (NASDAQ: ARGX) Phase 3 ADVANCE trial of Vyvgart (efgartigimod alfa-fcab) in adults with primary immune thrombocytopenia (ITP) met its primary endpoint. The ADVANCE trial enrolled 131 adult patients with chronic and persistent ITP.
- 05/05/2022
|
argenx to Present at BofA Securities 2022 Healthcare Conference
- May 4 , 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 10:40 a.m. P.T. in Las Vegas, NV.
- 05/04/2022
|
argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022
- April 28, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 5, 2022 at 2:30 pm CET (8:30 am ET) to discuss its first quarter 2022 financial results and provide a business update.
- 04/28/2022
|
argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
- BREDA, the Netherlands--(BUSINESS WIRE)--argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
- 04/01/2022
|
argenx (ARGX) Up on Positive Autoimmune Disorder Study Data
- argenx (ARGX) plans to file a BLA for the SC formulation of efgartigimod, developed using Halozyme's ENHANZE technology, for treating myasthenia gravis disease, an autoimmune disorder, in 2022.
- 03/23/2022
|
Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx
- Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical company" to run a clinical trial for LUNAR-COV19 vaccine candidate as a booster. According to analyst Yasmeen.
- 03/22/2022
|
Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder
- Argenx SE (NASDAQ: ARGX) ) has announced topline data from the Phase 3 ADAPT-SC study evaluating subcutaneous (SC) efgartigimod for generalized myasthenia gravis (gMG). Myasthenia gravis is a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles.
- 03/22/2022
|
argenx SE: Dutch Biotech Has Near Gain Ahead Says Hedging By Market-Makers
- argenx SE: Dutch Biotech Has Near Gain Ahead Says Hedging By Market-Makers
- 03/07/2022
|
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q4 2021 Results - Earnings Call Transcript
- argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q4 2021 Results - Earnings Call Transcript
- 03/03/2022
|
argenx to Present at the 42nd Annual Cowen Health Care Conference
- February 28, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the 42nd Annual Cowen Health Care Conference on Monday, March 7, 2022 at 2:10 p.m. E.T.
- 02/28/2022
|
Steven Cohen's Interest in IDEAYA Increases
- Steven Cohen (Trades, Portfolio), leader of Point72 Asset Management, disclosed earlier this week he increased his stake in IDEAYA Biosciences Inc. ( IDYA , Financial) by 52.12%.
- 02/25/2022
|
argenx to Report Full Year 2021 Financial Results and Fourth Quarter Business Update on March 3, 2022
- February 24, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, March 3, 2022 at 2:30 pm CET (8:30 am ET) to discuss its full year 2021 financial results and provide a fourth quarter business update.
- 02/24/2022
|
argenx to Present at the 11th Annual SVB Leerink Global Healthcare Conference
- February 10, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 10:40 a.m. ET.
- 02/10/2022
|
12 biotech stocks to consider buying now as prospects for the sector brighten this year
- Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double
- 02/06/2022
|
argenx to Present at 40th Annual J.P. Morgan Healthcare Conference
- January 3 , 202 2 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 7:30 a.m. ET.
- 01/03/2022
|
argenx: Vyvgart's Approval A Key Step For Continued Value Creation
- argenx received FDA approval for Vyvgart (efgartigimod) for the treatment of generalized myasthenia gravis. The label looks very favorable, and the only negative is that patients who do not have AChR antibodies are not included.
- 12/22/2021
|
Is Argenx a Good Biotech Stock to Buy for 2022?
- The recent approval of this drugmaker's first product is giving reasons to cheer now, but what about down the road?
- 12/20/2021
|
M&A madness: Top analyst on how biotech could rebound in 2022
- Michael Yee, Jefferies, on whether there's more M&A to come in the biotech space. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Steve Grasso, Pete Najarian and Karen Finerman.
- 12/15/2021
|
2 Mid-Cap Biopharma Stocks BofA Securities Recommends For 2022
- Biotech stocks are risky investments and to make a profit informed decision-making is needed. BofA Securities announced its top mid-cap biopharma picks in a note released Tuesday.
- 12/14/2021
|
argenx to Present at Upcoming Investor Conferences
- November 10, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that members of management will participate in several upcoming conferences:
- 11/10/2021
|
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q3 2021 Results - Earnings Call Transcript
- argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q3 2021 Results - Earnings Call Transcript
- 10/28/2021
|
argenx to Report Third Quarter 2021 Financial Results and Business Update on October 28, 2021
- October 21 , 202 1 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Thursday, October 28, 2021 at 2:30 pm CET (8:30 am ET) to discuss its third quarter 2021 financial results and provide a business update.
- 10/21/2021
|
argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming Neuromuscular Meetings
- Breda, the Netherlands – October 8 , 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancers, today announced the presentation of additional data from the Phase 3 ADAPT trial of efgartigimod for the treatment of generalized myasthenia gravis (gMG). The data will be presented at two upcoming neuromuscular meetings: the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting on October 13-16, 2021 in Aurora, CO and the virtual Myasthenia Gravis Foundation of America Scientific Session (MGFA) on October 30, 2021.
- 10/08/2021
|
argenx to Present at Upcoming Investor Conferences
- September 3, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that members of management will participate in several upcoming conferences:
- 09/03/2021
|
argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis
- Breda, the Netherlands – August 2 5 , 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it has submitted, and the European Medicines Agency (EMA) has validated, the marketing authorization application (MAA) for the Company's investigational FcRn antagonist, efgartigimod, for the treatment of generalized myasthenia gravis (gMG). Validation of the MAA confirms that the application is sufficiently complete to begin the formal review process.
- 08/25/2021
|
argenx: R&D Day Goes Unnoticed
- argenx: R&D Day Goes Unnoticed
- 08/23/2021
|
argenx to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference
- August 4, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that members of management will participate in a fireside chat at the 2021 Wedbush PacGrow Virtual Healthcare Conference on Wednesday, August 11, 2021 at 11:30 a.m. ET.
- 08/04/2021
|
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2021 Results - Earnings Call Transcript
- argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2021 Results - Earnings Call Transcript
- 08/01/2021
|
Recap: argenx Q2 Earnings
- Shares of argenx (NASDAQ:ARGX) decreased 4.8% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 162.86% over the past year to $1.98, which may not compared to the estimate of ($3.63).
- 07/29/2021
|
argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update
- - Completion of enrollment expected by year-end for ADAPT-SC and ADVANCE (IV) trials of efgartigimod; topline data for both trials expected in first half of 2022
- 07/29/2021
|
argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021
- July 22, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Thursday, July 29, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2021 financial results and provide a second quarter business update.
- 07/22/2021
|
argenx to Host Virtual R&D Day on July 20, 2021
- July 14, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a virtual R&D Day on Tuesday, July 20, 2021 at 3:00 p.m. CET (9:00 a.m. ET) to highlight its ‘argenx 2025 vision' and provide an update of its immunology pipeline. The event will introduce the fifth and sixth indications for the Company's FcRn antagonist, efgartigimod, and will include Phase 1 data from its C2 inhibitor, ARGX-117.
- 07/14/2021
|
argenx: Next Phase Of Growth With Efgartigimod And ARGX-117
- One of argenx's main competitors, Immunovant, suffered clinical setbacks this year and these setbacks have further solidified efgartigimod's potential best-in-class position. argenx to become a commercial-stage company by late-2021 with expected efgartigimod approval for generalized myasthenia gravis.
- 06/30/2021
|
argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology
- Results from ADAPT showed treatment with efgartigimod provided clinically meaningful improvement s in strength and quality of life measures in g eneralized m yasthenia g ravis (gMG )
- 06/16/2021
|
Argenx Is a Biotech Stock With Big Potential
- The company's main selling point is a drug called efgartigimod, which the company is testing in six different diseases.
- 06/15/2021
|
argenx (ARGX) to Regain AML Candidate After J&J's Dismissal
- argenx (ARGX) is developing cusatuzumab as potential treatment for acute myeloid leukemia. However, its partner, J&J, decided to discontinue the development agreement with the company for the candidate.
- 06/08/2021
|
Argenx Regains Global Rights from Johnson & Johnson to Blood Cancer Candidate Cusatuzumab
- Johnson & Johnson (NYSE: JNJ) has walked away from a $1.6 billion blood cancer candidate deal with Argenx SE (NASDAQ: ARGX) for the CD70-targeting cusatuzumab. The pair first came together to develop the med across various blood cancers and disorders in December 2018.
- 06/07/2021
|
argenx to regain global rights to cusatuzumab
- Regulated Information/Inside Information
- 06/07/2021
|
argenx Appoints Karl Gubitz as Chief Financial Officer
- June 1, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced the appointment of Mr. Karl Gubitz as Chief Financial Officer. Mr. Gubitz brings to argenx nearly 20 years of global pharmaceutical leadership experience, specifically in financial planning and analysis, business partnerships and product commercialization. He will succeed Eric Castaldi, who will remain with the company through June 30, 2021.
- 06/01/2021
|
argenx to Present at Upcoming Investor Conferences
- June 1, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that members of management will participate in the following upcoming investor conferences:
- 06/01/2021
|
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q1 2021 Results - Earnings Call Transcript
- argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q1 2021 Results - Earnings Call Transcript
- 05/14/2021
|
Recap: argenx Q1 Earnings
- Shares of argenx (NASDAQ:ARGX) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 60.68% year over year to ($0.81), which may not compare to the estimate of ($3.13).
- 05/14/2021
|
argenx Reports First Quarter 2021 Financial Results and Provides Business Update
- Japanese Marketing Authorization Application (J-MAA) for efgartigimod accepted for review by Japan's Pharmaceuticals and Medical Device Agency (PMDA) for generalized myasthenia gravis (gMG)
- 05/14/2021
|
argenx's Earnings Outlook
- argenx (NASDAQ:ARGX) releases its next round of earnings this Friday, May 14. Here is Benzinga's essential guide to argenx's Q1 earnings report.
- 05/13/2021
|
argenx announces results of Annual General Meeting of Shareholders
- May 1 1 , 20 2 1 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that the proposed resolutions presented at its Annual General Meeting of Shareholders, held today at 10:00 a.m. CEST, were duly passed.
- 05/11/2021
|
argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021
- May 7, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Friday, May 14, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its first quarter 2021 financial results and provide a business update.
- 05/07/2021
|
argenx Management to Present at Upcoming Virtual Investor Conferences
- April 28, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that members of management will participate in the following upcoming conferences:
- 04/28/2021
|
argenx announces Annual General Meeting of Shareholders on May 11, 2021
- March 30, 2021
- 03/30/2021
|
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q4 2020 Results - Earnings Call Transcript
- argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q4 2020 Results - Earnings Call Transcript
- 03/04/2021
|
argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update
- - Biologics License Application (BLA) for IV efgartigimod accepted for review by U.S. Food and Drug Administration (FDA) for generalized myasthenia gravis (gMG)
- 03/04/2021
|
argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021
- February 25, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on March 4, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its full year 2020 financial results and provide a fourth quarter business update.
- 02/25/2021
|
argenx announces closing of global offering
- Regulated information
- 02/05/2021
|
argenx announces full exercise of underwriters' option to purchase additional ADSs
- Regulated information — Inside information
- 02/04/2021
|
argenx raises $1.0 billion in gross proceeds in a global offering
- Regulated information — Inside information
- 02/02/2021
|
argenx Issues Statement Concerning Efgartigimod
- -No observed elevation of cholesterol markers related to treatment with efgartigimod
- 02/02/2021
|
argenx announces launch of proposed global offering
- Regulated information — Inside information
- 02/01/2021
|
argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis
- Regulated Information/Inside Information
- 02/01/2021
|
Week In Review: China Biopharma Starts 2021 With Over $1 Billion In Deals And IPOs
- Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up to $175 million in upfront and near-term payments.
- 01/10/2021
|
argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline
- Breda, the Netherlands – Jan. 8, 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancers, today announced its 2021 corporate priorities and highlighted recent achievements from its late-stage immunology pipeline driven by its FcRn antagonist, efgartigimod. Additionally, the Company announced interim data from the Phase 2 CULMINATE trial of cusatuzumab in development with Cilag GmbH International, an affiliate of Janssen, and provided financial guidance for 2021.
- 01/08/2021
|
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
|
argenx to Present at 39th Annual J.P. Morgan Healthcare Conference
- January 4, 2021 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 8:20 a.m. ET.
- 01/04/2021
|
argenx Enters Into Agreement To Acquire Priority Review Voucher
- November 23, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that the company has agreed to acquire a U.S. Food and Drug Administration (FDA) Priority Review Voucher (PRV) from Bayer Healthcare Pharmaceuticals, Inc for $98 million. A PRV entitles the holder to FDA priority review of a single New Drug Application or Biologics License Application (BLA), which reduces the target review time and may potentially lead to an expedited approval.
- 11/23/2020
|
argenx to Participate in Upcoming Virtual Investor Conferences
- November 9, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that management will participate in several upcoming investor conferences:
- 11/09/2020
|
argenx to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
- August 4, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 12:35 p.m. ET.A live webcast of the presentation will be available on the Company’s website at www.argenx.com. A replay of the webcast will be available for 90 days following the presentation.About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States and Japan. For more information, visit www.argenx.com and follow us on LinkedIn at https://www.linkedin.com/company/argenx/. For further information, please contact: Beth DelGiacco, Vice President, Investor Relations (US) +1 518 424 4980 bdelgiacco@argenx.com Joke Comijn, Director Corporate Communications & Investor Relations (EU) +32 (0)477 77 29 44 +32 (0)9 310 34 19 jcomijn@argenx.com
- 08/04/2020
|
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2020 Results - Earnings Call Transcript
- argenx SE (NASDAQ:ARGX) Q2 2020 Earnings Conference Call July 30, 2020 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Keith Woods - Chief Operating Officer Eric Castaldi - Chief Financial Officer Conference Call Participants Yaron Werber - Cowen Yatin Suneja - Guggenheim Jason Butler - JMP Securities Max Skor - Morgan Stanley Joon Lee - SunTrust Robinson Humphrey Tazeen Ahmad - Bank of America Merrill Lynch Graig Suvannavejh - Goldman Sachs Sandra Cauwenberghs - KBC Securities Presentation Beth DelGiacco Thank you.
- 08/02/2020
|
argenx SE 2020 Q2 - Results - Earnings Call Presentation
- The following slide deck was published by argenx SE in conjunction with their 2020 Q2 earnings call.
- 08/01/2020
|
argenx reports half year 2020 financial results and provides second quarter business update
- * Biologics License Application for efgartigimod in generalized myasthenia gravis on track to be submitted to U.S. Food and Drug Administration by end of year * Full data from ADAPT trial to be presented at upcoming medical meeting in 2020 * Cusatuzumab development strategy aligned with evolving AML treatment landscape to focus on combination with venetoclax and azacitidine * €1.9 billion in cash and cash equivalents and current financial assets strongly support commercial launch preparation of efgartigimod * Management to host conference call today at 2:30 pm CEST (8:30 am ET) July 30, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced its half year 2020 financial results and provided a second quarter business update and outlook for the remainder of the year.“We are proud of the progress we have made during the first half of 2020 to advance our immunology pipeline and validate our first-in-class FcRn antagonist, efgartigimod. We announced positive topline results from the Phase 3 ADAPT trial, furthering our conviction that efgartigimod has the potential to significantly improve the standard of care for people with gMG as well as several other autoantibody-driven diseases. We are focused on our planned 2021 U.S. commercial launch of efgartigimod to bring this therapy to patients as quickly as possible and to advance on our ‘argenx 2021’ vision,” said Tim Van Hauwermeiren, CEO of argenx."We also remain committed to advancing our robust pipeline, including our late-stage efgartigimod trials in additional autoimmune indications and our early-stage candidates from our Immunology Innovation Program. Regarding cusatuzumab, which we are currently developing in a global collaboration with Janssen, as clinical trial sites re-open, we are taking the opportunity to evaluate the most appropriate development strategy given the rapidly evolving treatment landscape, ” continued Mr. Van Hauwermeiren. SECOND QUARTER 2020 AND RECENT BUSINESS UPDATEargenx continues to execute on its “argenx 2021” vision to become a fully integrated, global immunology company. The company continues to implement measures across the organization and in the operations of globally run clinical trials to minimize the impact of COVID-19 on employees, patients and their communities, physicians and ongoing business priorities. Commercial preparations underway to support potential approval and launch of argenx’s first-in-class FcRn antagonist, efgartigimod, in its first indication, generalized myasthenia gravis (gMG). * Biologics License Application (BLA) on track to be filed with the U.S. Food and Drug Administration (FDA) by the end of 2020 with an expected U.S. commercial launch in 2021 * Japanese Marketing Authorization Application (J-MAA) expected to be filed with the Pharmaceuticals and Medical Devices Agency (PMDA) in the first half of 2021 with an expected efgartigimod launch in gMG in Japan following the U.S. commercial launch * Commercial infrastructure readiness activities, including with global supply chain, are on track for launch timeline in the U.S. and Japan In May, argenx reported positive topline data from the Phase 3 ADAPT trial showing efgartigimod was well-tolerated and able to drive responses that support plans to offer individualized dosing to gMG patients. * ADAPT met its primary endpoint showing 67.7% of acetylcholine receptor-antibody positive (AChR-Ab+) gMG patients were responders on the Myasthenia Gravis Activities of Daily Living (MG-ADL) score compared with 29.7% on placebo (p<0.0001) * 63.1% of AChR-Ab+ gMG patients responded to efgartigimod compared with 14.1% on placebo on the Quantitative Myasthenia Gravis (QMG) score (p<0.0001) * 40.0% of efgartigimod-treated AChR-Ab+ patients achieved minimal symptom expression defined as MG-ADL scores of 0 (symptom free) or 1, compared to 11.1% treated with placebo * In AChR-Ab+ patients who met the primary endpoint, the majority showed a sustained response, including 88.6% who achieved a response for at least six weeks, 56.8% for at least eight weeks and 34.1% for at least 12 weeks * Safety profile of efgartigimod was comparable to placebo * Detailed data set to be presented at upcoming medical meeting in 2020 * argenx plans to meet with FDA in fourth quarter of 2020 to discuss bridging strategy for subcutaneous (SC) efgartigimod Positive ADAPT data support continued progress of efgartigimod in additional severe autoimmune indications within key commercial franchises. * Primary immune thrombocytopenia (ITP) registrational program includes ongoing ADVANCE trial evaluating 10mg/kg IV efgartigimod in up to 156 patients * Enrollment delays in the program have been observed due to COVID-19 * Discussions ongoing with FDA on how to bring forward SC components of program to meet COVID-19 enrollment challenges * Chronic inflammatory demyelinating polyneuropathy (CIDP) Phase 2 ADHERE trial ongoing evaluating SC efgartigimod * Due to COVID-19 enrollment delays, potential decision to expand trial up to 130 patients now expected in 2021 * Pemphigus vulgaris (PV) registrational trial to start in second half of 2020 following proof-of-concept data from adaptive Phase 2 trial that showed fast onset of disease control and deep responses with potential for steroid sparing * Fifth indication to be announced by end of 2020 Cusatuzumab development strategy aligned with evolving treatment landscape and anticipated global adoption of venetoclax in acute myeloid leukemia (AML) clinical practice. * Development plan, in collaboration with Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, to now focus on cusatuzumab in combination with venetoclax, including in the Phase 1b ELEVATE combination trial of cusatuzumab with venetoclax and azacitidine in newly diagnosed, elderly patients with AML who are ineligible for intensive chemotherapy * Trial enrolling again after pause due to COVID-19 * Maturing data from Phase 2 CULMINATE trial of cusatuzumab in combination with azacitidine in newly diagnosed, elderly patients with AML who are ineligible for intensive chemotherapy suggest that complete response rates are not likely to exceed those from the VIALE-A trial of venetoclax in combination with azacitidine presented at the European Hematology Association (EHA) Annual Congress in June 2020 * Based on enrollment to date, dose selected to be 20mg/kg * CULMINATE trial will continue to evaluate responses and durability for existing patients but will not enroll new patients * Topline data to be reported in early 2021 * Registration strategy to be determined following evaluation of maturing data across cusatuzumab program and AML treatment landscape * Phase 1 trial of cusatuzumab in combination with azacitidine trial in Japan evaluating newly diagnosed, elderly AML patients who are ineligible for intensive chemotherapy remains ongoing * Phase 2 BEACON trial of cusatuzumab in combination with azacitidine versus azacitidine alone in higher-risk patients with myelodysplastic syndromes (MDS) who are ineligible for intensive chemotherapy remains paused for enrollment * Part 1 dose escalation of Phase 1 study of cusatuzumab in combination with azacitidine in newly diagnosed, elderly patients with AML who are ineligible for intensive chemotherapy, published in Nature Medicine argenx continues to advance its early-stage pipeline of first-in-class antibodies against immunologic targets.
- 07/30/2020
|
Earnings Preview: argenx
- On Thursday, July 30, argenx (NASDAQ: ARGX) will release its latest earnings report. Benzinga's outlook for argenx is included in the following report.Earnings and Revenue argenx EPS will likely be near $-2.7 while revenue will be around $22.22 million, according to analysts. argenx's loss in the same period a year ago was $-1.120 per share. Quarterly sales came in at $7.83 million. If the company were to match the consensus estimate, earnings would be down 141.07%. Revenue would be up 29.94% from the year-ago period. In comparison to analyst estimates in the past, here's how the company's reported EPS stacks up:Quarter Q1 2020 Q4 2020 Q3 2019 Q2 2019 EPS Estimate -1.56 -1.10 -1.34 -0.91 EPS Actual -2.06 -2.63 -0.72 -1.12 Revenue Estimate 17.10 M 21.84 M 17.30 M 17.47 M Revenue Actual 21.15 M 19.45 M 9.52 M 7.83 M Stock Performance Shares of argenx were trading at $253.23 as of July 29. Over the last 52-week period, shares are up 75.8%. Given that these returns are generally positive, long-term shareholders should be content going into this earnings release.View more earnings on ARGXDon't be surprised to see the stock move on comments made during its conference call. argenx is scheduled to hold the call at 09:00:00 ET and can be accessed here: https://edge.media-server.com/mmc/p/wc62shzrSee more from Benzinga * Benzinga's Top Upgrades, Downgrades For July 29, 2020 * Stocks That Hit 52-Week Highs On Friday * Stocks That Hit 52-Week Highs On Thursday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/29/2020
|
Did Hedge Funds Make The Right Call On argenx SE (ARGX) ?
- The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
- 07/20/2020
|
argenx (ARGX): Strong Industry, Solid Earnings Estimate Revisions
- argenx (ARGX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 07/01/2020
|
Is argenx SE (ARGX) A Good Stock To Buy?
- Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
- 06/15/2020
|
argenx announces closing of global offering
- Breda, the Netherlands / Ghent, Belgium — argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today the closing of its previously announced global offering of an aggregate of 4,207,292 ordinary shares (including ordinary shares represented by American Depositary Shares (ADSs)), which includes the full exercise of the underwriters’ option to purchase 548,777 additional ADSs. Stifel, JMP Securities, Wedbush PacGrow, Nomura and Kempen & Co acted as co-managers for the offering. The securities were offered in the United States pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission (SEC).
- 06/01/2020
|
argenx announces full exercise of underwriters’ option to purchase additional ADSs
- Breda, the Netherlands / Ghent, Belgium — argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today that the underwriters of its previously announced global offering of ordinary shares (including ordinary shares represented by American Depositary Shares (ADSs)) have exercised their option to purchase 548,777 additional ADSs in full on the same terms and conditions as the global offering. This option exercise brings the anticipated total gross proceeds from the global offering to approximately $862.5 million (approximately €784.7 million) from the sale of an aggregate of 4,207,292 ordinary shares (including ordinary shares represented by ADSs).
- 05/29/2020
|
argenx raises $750 million in gross proceeds in a global offering
- Breda, the Netherlands / Ghent, Belgium — argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today the pricing of a global offering of ordinary shares represented by American Depository Shares (ADSs) in the United States and certain other countries outside of European Economic Area and a simultaneous private placement of ordinary shares in the European Economic Area. The Company anticipates total gross proceeds of approximately $750.0 million (approximately €682.4 million) from the sale of 2,584,138 ADSs at a price of $205.00 per ADS and the sale of 1,074,377 ordinary shares at a price of €186.52 per ordinary share.
- 05/28/2020
|
argenx Up on Positive Data from Pivotal Efgartigimod Study
- argenx's (ARGX) lead pipeline candidate, efgartigimod, meets primary endpoint in a pivotal study evaluating it in myasthenia gravis. A BLA is likely to be filed by the end of 2020.
- 05/27/2020
|
The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) * ADC Therapeutics SA (NYSE: ADCT) (IPOed May 15) * Aeglea Bio Therapeutics Inc (NASDAQ: AGLE)(announced positive one-year Phase 1/2 study and Phase 2 open-label extension study of pegzilarginase in Arginase 1 Deficiency patients) * Allogene Therapeutics Inc (NASDAQ: ALLO) * Altimmune Inc (NASDAQ: ALT) * argenx SE - ADR (NASDAQ: ARGX)( announced positive top-line data from a late-stage study of efgartigimod in patients with generalized Myasthenia Gravis) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)(gained on sell-side comment on the company being a potential target for Sanofi SA (NASDAQ: SNY) * Bio-Rad Laboratories, Inc. (NYSE: BIO) * Castle Biosciences Inc (NASDAQ: CSTL) * Catalent Inc (NYSE: CTLT) * ChemoCentryx Inc (NASDAQ: CCXI) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) * Cue Biopharma Inc (NASDAQ: CUE) * Evoke Pharma Inc (NASDAQ: EVOK) * Fate Therapeutics Inc (NASDAQ: FATE) * GENMAB A/S/S ADR (NASDAQ: GMAB) * Harpoon Therapeutics Inc (NASDAQ: HARP) * Horizon Therapeutics PLC (NASDAQ: HZNP) * Immunomedics, Inc. (NASDAQ: IMMU) * Immunovant Inc (NASDAQ: IMVT) * Intellia Therapeutics Inc (NASDAQ: NTLA) * Iovance Biotherapeutics Inc (NASDAQ: IOVA) * Kala Pharmaceuticals Inc (NASDAQ: KALA)(announced FDA acceptance of its regulatory filing for Eysuvis, 0.25%, to treat the signs and symptoms of dry eye disease) * Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) * MEI Pharma Inc (NASDAQ: MEIP) * Mersana Therapeutics Inc (NASDAQ: MRSN) * Minerva Neurosciences Inc (NASDAQ: NERV) * Neurocrine Biosciences, Inc. (NASDAQ: NBIX) * Ovid Therapeutics Inc (NASDAQ: OVID) * Passage Bio Inc (NASDAQ: PASG) * PDL BioPharma Inc (NASDAQ: PDLI) * Prevail Therapeutics Inc (NASDAQ: PRVL) * Protara Therapeutics Inc (NASDAQ: TARA)(received Fast Track designation for intravenous choline chloride for the treatment of intestinal failure associated liver disease) * Qiagen NV (NYSE: QGEN) * Seres Therapeutics Inc (NASDAQ: MCRB) * Strongbridge Biopharma plc (NASDAQ: SBBP) * TG Therapeutics Inc (NASDAQ: TGTX)Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 26) * Conatus Pharmaceuticals Inc (NASDAQ: CNAT) * Related Link: Merck's Coronavirus Plan Of Attack: 2 Partnerships, M&A; Deal Aimed At Treatment, Vaccine DevelopmentStocks In Focus Cumberland Announces Publication of Positive Data For FDA-approved Antibiotic In Treating Bacteremia and Endocarditis Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) announced a new publication in Drugs - Real World Outcomes, detailing the positive clinical outcomes with Vibativ in treating patients with bacteremia or endocarditis.Vibativ has been approved by the FDA for the treatment of serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia. It is also approved for complicated skin and skin structure infections.The stock jumped 31.92% to $4.67 in after-hours trading.Bristol-Myers Squibb Opdivo/Yervoy Combo Approved First-Line Lung Cancer Treatment Bristol-Myers Squibb Co (NYSE: BMY) announced FDA approval for Opdivo 360 mg plus Yervoy 1 mg/kg, given with two cycles of platinum-doublet chemotherapy for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations.The therapy is approved for patients with squamous or non-squamous disease and regardless of PD-L1 expression, the company said.Astellas Gets Label Expansion For Bladder Dysfunction Drug ASTELLAS PHARMA/ADR (OTC: ALPMY) said the approved its VESIcare LS oral suspension, a liquid taken by mouth, for the treatment of neurogenic detrusor overactivity, a form of bladder dysfunction related to neurological impairment, in children ages two years and older. VESIcare tablets were initially approved in 2004 for the treatment of overactive bladder in adults 18 years and older.Coherus To Join S&P; SmallCap 600 Index Coherus Biosciences Inc (NASDAQ: CHRS) is set to join the S&P; 500 SmallCap 600 Index, replacing Opus Bank (NASDAQ: OPB), effective June 1.In after-hours trading, the stock rallied 8.20% to $18.35.Mersana ADC Conjugate Found Safe, Effective Mersana announced interim data from the ongoing expansion portion of the Phase 1 study evaluating XMT-1536 in patients with ovarian cancer and non-small cell lung adenocarcinoma. Of the 20 ovarian cancer patients, 10% achieved confirmed complete response and 25% confirmed partial responses, rendering the overall response rate at 35%. It was also found to be generally well tolerated.These data are to be presented at the ASCO 2020 Virtual Scientific Program.Teligent To Effect 1-for-10 Reverse Stock Split Teligent Inc (NEW JERSEY) (NASDAQ: TLGT) said a 1-for-10 reverse stock split of its common stock will take effect as of May 28.Novartis Announces Positive Data For Multiple Sclerosis, Breast Cancer Drugs Novartis AG (NYSE: NVS) announced new data from the Phase 3 ASCLEPIOS study and the Phase 2 APLIOS study that is evaluating its B-cell therapy ofatumumab in patients with relapsing multiple sclerosis, or RMS. These data were virtually presented at the 6th Congress of the European Academy of Neurology.The Phase 3 study, which evaluated ofatumumab versus teriflunomide within the first and second year of treatment, showed a greater proportion of patients treated with ofatumumab achieved NEDA-3 - a comprehensive composite measure used to measure outcomes in patients with RMS - both in year 1 and year 2.A separate analysis from the APLIOS Phase 2 trial, evaluating 284 RMS patients, showed ofatumumab treatment led to rapid and sustained depletion of both CD20+ B- and T-cells in patients with RM3.The FDA is set to rule on ofatumumab in June.Separately, Novartis announced a new exploratory subgroup analysis of the Phase 3 MONALEESA-3 and MONALEESA-7 trials, to be presented during the ASCO 2020 Virtual Scientific Program, which reinforced the overall survival benefit of Kisqali in HR+/HER2- advanced breast cancer.Sonoma's Eye Care Product Gets CE Marking; Company Announces Expanded Agreement With European Distribution Partner Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) announced it received a new CE Marking for its Microdacyn60 Eye Care based on its patented Microcyn Technology. The formulation, according to the company, is a safe and efficacious method to keep areas around the eye and eyelids/eyelashes clean and remove foreign materials.View more earnings on IBBThe company also announced a new 10-year license, distribution and supply agreement with its distribution partner Brill International to market the eye care product under the private label Ocudox in the European markets of Italy, Germany, Spain, Portugal and the U.K.,subject to Brill meeting certain annual minimum purchase requirements.The stock gained 7.81% to $5.80 in after-hours trading.Roche Announces Positive Late-Stage Results Of Port Delivery System With Ranibizumab In Wet Age-Related Macular Degeneration Roche Holdings (OTC: RHHBY) announced positive top-line results from the phase 3 Archway study evaluating Port Delivery System, or PDS, with ranibizumab in people living with neovascular or wet age-related macular degeneration.PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customized formulation of ranibizumab over a period of months.Offerings Atara Biotherapeutics Inc (NASDAQ: ATRA) priced its underwritten public offering of 12.63 million of its common stock at $11.32 per share, and pre-funded warrants to purchase 2.87 million of its common stock at $11.3199 per pre-funded warrant share.The company expects to generate gross proceeds of $175.5 million from the offering. The offering is expected to close on or about May 29.Medical device maker Neovasc Inc (NASDAQ: NVCN) announced an offering of convertible notes and warrants to Stur Medical Group for gross proceeds of up to $5 million. The company also said all of its remaining 2017 notes have been fully paid or converted. The combined transactions, according to the company, will improve the fully diluted share capital, likely allowing to pursue refinancing options with long-term investors.argenx SE - ADR (NASDAQ: ARGX), which announced Tuesday a positive clinical readout, said it has commenced a global offering of $500 million of ordinary shares, which may be represented by ADSs.NuVasive, Inc. (NASDAQ: NUVA) said it intends to offer $400 million aggregate principal amount of convertible senior Notes due 2023 in a private placement to qualified institutional buyers.Zomedica Pharmaceuticals Corp (NYSE: ZOM) priced its public offering of 133.33 million shares of its common stock, along with warrants to purchase up to 133.33 million common stock, at a combined 15 cents per share and accompanying warrant.Fortress Biotech (NASDAQ: FBIO) said it has priced an underwritten public offering of 555,556 shares of its 9.375% Series A cumulative redeemable perpetual preferred stock at a price of $18 per share, with expected gross proceeds to Fortress of about $10 million.Sanofi priced its registered offering of 11.8 million shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) at $515 per share. As previously announced, Regeneron will repurchase about 9.8 million shares or $5 billion in common stock from Sanofi. Sanofi said it expects to use the net proceeds of the offering and the repurchase to further execute on its strategy to drive innovation and growth.
- 05/27/2020
|
argenx announces launch of proposed global offering
- Breda, the Netherlands / Ghent, Belgium — argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today that it has commenced a global offering of $500 million (approximately €458.3 million) of ordinary shares, which may be represented by American Depository Shares (“ADSs”). The global offering will be comprised of an offering of ordinary shares represented by ADSs in the United States and certain other countries outside of the European Economic Area and a simultaneous private placement of ordinary shares in the European Economic Area.
- 05/26/2020
|
Here's Why argenx Stock Is Soaring Today
- Shares of argenx (NASDAQ: ARGX), a clinical-stage biotechnology company, are on the move following positive results from the Adapt trial of efgartigimod. An impressive 67.7% of those treated with efgartigimod achieved improvements on their myasthenia gravis activities of daily living (MG-ADL) scores of at least two points. Myasthenia gravis is a relatively rare immune disorder that weakens patients by jamming up the transmission of signals between their brains and their muscle fibers.
- 05/26/2020
|
argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis
- Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced positive topline data from the pivotal ADAPT trial of efgartigimod. ADAPT met its primary endpoint defined as percentage of responders on the Myasthenia Gravis Activities of Daily Living (MG-ADL) score among acetylcholine receptor-antibody positive (AChR-Ab+) generalized myasthenia gravis (gMG) patients.
- 05/26/2020
|
argenx SE (ARGX) Q1 2020 Earnings Call Transcript
- A press release with our first quarter 2020 business update and financial results was issued earlier today and can be found on our website along with the presentation for today's webcast. Thank you, Beth and welcome everyone.
- 05/14/2020
|
argenx reports first quarter 2020 financial results and provides business update
- - Topline data readout from Phase 3 ADAPT trial of efgartigimod in generalized myasthenia gravis on track for mid-2020 and Biologics License Application filing.
- 05/14/2020
|
Halozyme (HALO) Q1 Earnings and Revenues Miss Estimates
- Halozyme (HALO) reports wider-than-expected Q1 loss. Shares down.
- 05/12/2020
|
The argenx (EBR:ARGX) Share Price Gained 1374% And Shareholders Are Jubilant
- We think all investors should try to buy and hold high quality multi-year winners. While not every stock performs...
- 05/11/2020
|
7 “Strong Buy” Healthcare Stocks to Buy Now
- As the month of May kicked off, stocks got off to a rocky start. The market slumped in response to a first quarter profit miss from eCommerce giant Amazon (NASDAQ:AMZN) and its plan to put all second-quarter earnings towards its COVID-19 response, with all three of the major U.S. indexes landing in the red on the week's final day of trading. Aside from healthcare stocks, many also came under pressure as tensions between the U.S. and China flared after the Trump administration stated that China will be held accountable for COVID-19. May 1's disappointing trading session came on the heels of the largest monthly surge for Wall Street in more than three decades. However, that's not to say investors should hold off on all new additions to their portfolios. The investing pros note that it's still possible to unmask the names poised to take off on an upward trajectory, you just have to know what to look for. This is especially true of the healthcare space, which has managed to hold up significantly better than other industries. Advising careful due diligence, they recommend focusing on healthcare stocks the analyst community as a whole believes have healthy long-term growth prospects. InvestorPlace - Stock Market News, Stock Advice & Trading TipsOnce we knew what to watch out for, we used TipRanks' database to pinpoint seven compelling healthcare stocks: * Ascendis Pharma A/S (NASDAQ:ASND) * Argenx SE (NASDAQ:ARGX) * Amicus Therapeutics, Inc. (NASDAQ:FOLD) * Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) * Natera, Inc. (NASDAQ:NTRA) * United Therapeutics Corporation (NASDAQ:UTHR) * Axsome Therapeutics Inc. (NASDAQ:AXSM) * 10 Key Stocks to Watch Over the Next Few Months Each of these healthcare stocks is backed by several analysts, enough to earn a "strong buy" consensus rating. Not to mention some pretty impressive upside potential is on the table. Let's dive right in. Ascendis Pharma (ASND) Source: Shutterstock The first of our healthcare stocks to buy is Ascendis Pharma. Using its cutting-edge TransCon technology, Ascendis optimizes the dosing capabilities of products that are already on the market. Following a recent Phase 2 data readout, several members of the Street are even more excited about this stock's long-term growth prospects. Writing for Oppenheimer, analyst Leland Gershell argues that the results clearly demonstrate TransCon PTH has the potential to be a "true replacement therapy in patients with hypoparathyroidism." In the 21µg/day arm, which was the highest dose, nine out of 15 patients met each of the primary and secondary composite endpoints. All patients were able to eliminate the standard of care (SOC). Adding to the good news, there was a positive effect on renal calcium resorption. Gershell added, "No severe or serious adverse events were recorded, nor was any hypocalcemia during titration off SOC. Hypercalcemia was observed in 2/15 (13%) in 21µg/day cohort w/o clinical sequelae. We would expect dose tailoring on an individual basis, as would occur in practice vs. trial's fixed dosing, to be supportive to safety." Looking forward to the initiation of Phase 3 in the fourth quarter, Gershell sees a large market opportunity, with the worldwide target market coming in at 200,000 and at 70,000-112,000 for the U.S. Taking all of this into consideration, Gershell decided to stay on the bulls' side. Along with his "outperform" call, he also bumped up the price target to $219, implying 71% upside potential. Out of nine total ratings, 100% were bullish, making ASND's Street consensus a "strong buy." See the ASND stock analysis. Argenx SE (ARGX) Source: Shutterstock When it comes to Argenx, there is certainly some overhang. Cowen analyst Yaron Werber points out that full year 2019 was solid for ARGX, but there's more to the story. Several competing FcRn-targeting drugs in the MG space, including Immunovant's IMVT-1401 and Momenta's M281, have upcoming data readouts. These candidates appear to be well-tolerated and have previously shown upwards of 70-80%+ knockdown of IgG. However, the Cowen analyst believes ARGX's lead candidate, efgartigimod, can go head-to-head with these other therapies. "We believe that ARGX's efgartigimod has a potentially best-in-class profile with a first mover advantage across several indications (MG, ITP, PV and CIDP) while offering both IV and SQ formulations. Efgartigimod is eying lucrative multi-billion dollar markets. Our peak $2.3 billion in sales is based on a peak 30% share in MG and ITP with a 75% probability of success. Approval in both segments offers attractive upside before even considering the potential in other indications," Werber commented. As autoimmune disorders like MG, ITP, PV and CIDP still have unmet needs because the current available options like steroids and immunosuppressants have poor tolerability and IVIg is expensive, inconvenient, and faces capacity constraints, favorable Phase 3 MG data in mid-2020 and the BLA filing in MG in Q4 2020 could drive substantial upside in 2020. To this end, Werber left an "outperform" rating and $191 price target on the stock. Should this target be met, a twelve-month gain of 31% could be in store. * 7 A-Rated REITs to Buy Now Does the rest of the Street think ARGX can outperform in the long run? As it turns out, other analysts say yes. Six "buys" compared to no "holds" or "sells" assigned in the last three months add up to a "strong buy" consensus rating. At $194.36, the average price target puts the upside potential at 34%. See the ARGX stock analysis. Amicus Therapeutics (FOLD) Source: Shutterstock Amicus Therapeutics specializes in developing better therapies to help patients suffering from ultra-orphan diseases, including lysosomal storage disorders (LSDs). As one of its lead programs has already been well received post-launch, one analyst believes the healthcare company's future is only getting brighter. Its oral pharmaco-chaperone drug, Galafold, for Fabry, generated hefty sales of $55.3 million in Q4 2019. Not only did this top-line number beat the Street's $49.7 million call, but it also surpassed Cowen analyst Ritu Baral's $50.5 million estimate. Not to mention this result represents 13% quarter-over-quarter growth. Even though FOLD had a net loss of $91 million during the quarter and SG&A; expense gained 9% quarter-over-quarter, it should be noted that this was in part caused by the expanded geographic scope of the launch of Galafold into Japan and the U.S. Baral added, "FOLD projects YE20 Galafold sales of $250-$260 million that would represent 37-43% year-over-year growth. Projected growth assumes maturing uptake in the EU top 5 countries (market share changing from ERT-switch to ERT-naive) and continued rapid uptake in US and non-top 5 EU countries. FOLD expects to see commercial sales from Latin American countries in 2021 to further drive topline growth." To top it all off, GTx pipeline development is continuing. CLN6 follow-up and initial CLN3 data are both slated for the second half of 2020. It should come as no surprise, then, that Baral kept an "outperform" call and $31 price target on the stock. This conveys her confidence in FOLD's ability to soar 174% in the next year. As for the rest of the Street, other analysts are in agreement. With three "buys" and one "hold," the word on the Street is that the healthcare name is a "strong buy." Based on the $21.17 average price target, shares could climb 87% higher in the next twelve months. See the FOLD stock analysis. Iovance Biotherapeutics (IOVA) Source: Shutterstock Next up on this list of healthcare stocks to buy is Iovance Biotheraputics. With the goal of stomping out cancer, Iovance develops transformative immuno-oncology tumor-infiltrating lymphocytes (TIL) therapies that use the power of a patient's own immune system. After its collaborator, Moffitt Cancer Center, provided an update on the Phase 1 testing of TILs plus nivolumab in CKI-naive metastatic non-small-cell lung carcinoma (NSCLC) patients, the stock is on Wall Street's radar. In order to be eligible, patients needed to be anti-PD-1 naive and at least one safely accessible metastasis from where TILs were isolated had to be present. Looking at the data, the therapy was effective in 25% of patients, with two complete responses recorded. On top of this, the key analysis indicates that in order to spur a clinical response, TILs need to survive and circulate systematically. Further explaining this, H.C. Wainwright's Joseph Pantginis noted, "Importantly, the authors also demonstrated that neoantigen positive T cells represented 21% of total TIL clonotypes. Although TIL clonotype persistence declines with time in the blood of these patients, persistent and stable levels of infused T cells associated with higher tumor killing and response. Thus, we believe that methods to enrich for these TIL populations, such as Iovance's next generation TILs could be critical to drive better clinical responses." As NSCLC is a notoriously difficult indication to address, Pantginis argues that the results should be interpreted as a major positive. With this in mind, he left a "buy" rating on IOVA. Along with his bullish call, the analyst lifted the price target from $36 to $48. This brings the upside potential to 50%. * 10 Healthcare Stocks to Buy Despite the Headlines With 100% Street support, or nine "buy" ratings set in recent months, the consensus is unanimous: IOVA is a "strong buy." See the IOVA stock analysis. Natera (NTRA) Source: Shutterstock At the core of Natera's mission, it hopes its innovative technology will deliver highly accurate solutions for noninvasive prenatal testing (NIPT), genetic-carrier screening, (PGD/PGS) as well as miscarriage testing.
- 05/08/2020
|
Comparing argenx (NASDAQ:ARGX) & Rubius Therapeutics (NASDAQ:RUBY)
- Rubius Therapeutics (NASDAQ:RUBY) and argenx (NASDAQ:ARGX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, earnings, dividends and profitability. Profitability This table compares Rubius Therapeutics and argenx’s net margins, return on equity and return on assets. […]
- 04/27/2020
|
Bank of New York Mellon Corp Acquires 2,096 Shares of argenx SE - (NASDAQ:ARGX)
- Bank of New York Mellon Corp raised its stake in argenx SE – (NASDAQ:ARGX) by 36.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,868 shares of the company’s stock after acquiring an additional 2,096 shares during the quarter. Bank of New […]
- 04/25/2020
|
argenx SE - (NASDAQ:ARGX) Expected to Post Quarterly Sales of $17.21 Million
- Equities research analysts expect that argenx SE – (NASDAQ:ARGX) will announce sales of $17.21 million for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for argenx’s earnings, with the lowest sales estimate coming in at $9.99 million and the highest estimate coming in at $24.87 million. The company is expected to […]
- 04/24/2020
|
Arden Trust Co Makes New Investment in argenx SE - (NASDAQ:ARGX)
- Arden Trust Co purchased a new position in argenx SE – (NASDAQ:ARGX) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 655 shares of the company’s stock, valued at approximately $86,000. A number of other large investors also recently bought and sold shares […]
- 04/20/2020
|
argenx SE - (NASDAQ:ARGX) Sees Significant Drop in Short Interest
- argenx SE – (NASDAQ:ARGX) was the target of a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 917,900 shares, a drop of 12.1% from the March 15th total of 1,043,900 shares. Based on an average daily trading volume, of 160,200 shares, the days-to-cover ratio […]
- 04/20/2020
|
Bank of America Corp DE Boosts Holdings in argenx SE - (NASDAQ:ARGX)
- Bank of America Corp DE lifted its stake in argenx SE – (NASDAQ:ARGX) by 302.9% in the 4th quarter, HoldingsChannel reports. The firm owned 25,055 shares of the company’s stock after buying an additional 18,836 shares during the quarter. Bank of America Corp DE’s holdings in argenx were worth $4,021,000 at the end of the […]
- 04/15/2020
|
Franklin Resources Inc. Raises Position in argenx SE - (NASDAQ:ARGX)
- Franklin Resources Inc. grew its holdings in shares of argenx SE – (NASDAQ:ARGX) by 20.1% during the fourth quarter, HoldingsChannel reports. The firm owned 623,968 shares of the company’s stock after purchasing an additional 104,441 shares during the quarter. Franklin Resources Inc.’s holdings in argenx were worth $100,160,000 at the end of the most recent […]
- 04/04/2020
|
Analyzing Sutro Biopharma (NASDAQ:STRO) & argenx (NASDAQ:ARGX)
- Sutro Biopharma (NASDAQ:STRO) and argenx (NASDAQ:ARGX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation. Profitability This table compares Sutro Biopharma and argenx’s net margins, return on equity and return on assets. […]
- 03/31/2020
|
Selloff creating bargains in healthcare - Baird
- Stating the obvious, Baird analysts have created three lists of healthcare companies that may be worth a look considering their attractive valuations or relatively strong capitalizations amid the COVI
- 03/25/2020
|
WABCO Holdings Inc. (WBC): Are Hedge Funds Right About This Stock?
- Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
- 03/23/2020
|
Hedge Funds Have Never Been This Bullish On Arrow Electronics, Inc. (ARW)
- Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
- 03/23/2020
|
Dolby Laboratories, Inc. (DLB): Hedge Funds Were Snapping Up Before The Coronavirus
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 03/23/2020
|
Here is What Hedge Funds Think About Watsco Inc (WSO)
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 03/23/2020
|
argenx SE (ARGX): Hedge Funds In Wait-and-See Mode
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 03/23/2020
|
Argenx: The Upside Is Still There
- Efgartigimod is set to change treatment paradigm in MG indication. Efgartigimod has also demonstrated promising efficacy in additional indications. Collaboratio
- 03/04/2020
|
Argenx Se (ARGX) Received its Third Buy in a Row
- After Merrill Lynch and Guggenheim gave Argenx Se (NASDAQ: ARGX) a Buy rating last month, the company received another Buy, this time from Cowen & Co.
- 03/04/2020
|
Argenx Se (ARGX) Received its Third Buy in a Row
- After Merrill Lynch and Guggenheim gave Argenx Se (NASDAQ: ARGX) a Buy rating last month, the company received another Buy,
- 03/04/2020
|
Wall Street Analysts Are Bullish on Top Healthcare Picks
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Argenx Se (ARGX) and Momenta Pharma (MNTA) with bullish
- 02/27/2020
|
Wall Street Analysts Are Bullish on Top Healthcare Picks
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Argenx Se
- 02/27/2020
|
Top Ranked Momentum Stocks to Buy for February 27th
- Top Ranked Momentum Stocks to Buy for February 27th
- 02/27/2020
|
Top Ranked Momentum Stocks to Buy for February 27th
- Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 27th
- 02/27/2020
|
argenx reports full year 2019 financial results and provides fourth quarter business update
- Topline data from Phase 3 ADAPT trial of efgartigimod in gMG expected in mid-2020Continued progress across broadest FcRn antagonist pipeline with up to five.
- 02/27/2020
|
Our Take On argenx SE's (EBR:ARGX) CEO Salary
- In 2008 Tim Van Hauwermeiren was appointed CEO of argenx SE (EBR:ARGX). First, this article will compare CEO...
- 02/09/2020
|
Head to Head Comparison: argenx (NASDAQ:ARGX) & PDL BioPharma (NASDAQ:PDLI)
- PDL BioPharma (NASDAQ:PDLI) and argenx (NASDAQ:ARGX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability. Institutional & Insider Ownership 87.1% of PDL BioPharma shares are held by institutional investors. Comparatively, 58.7% of […]
- 01/19/2020
|
These 3 Healthcare Stocks Are Set to Soar in 2020, Says Cowen
- The calendar might have flipped to 2020, but that doesn’t mean everything has changed. Investors are still scouring the Street in search of the most compelling investment opportunities, the names that could see 2020 be their year.These aren’t just any run of the mill stocks. We’re talking about tickers that are set to outperform the broader market and can hand over substantial returns in the year ahead. Having said that, tackling this job isn’t always easy. With so many options out there, it can seem overwhelming. Luckily, Wall Street analysts are here to lend a hand.Often experts in the industries that they cover, a nod of approval from the Street’s seasoned pros can signal that a certain stock should be on investors’ radar. Bearing this in mind, we turned to the analysts at investing firm Cowen for some inspiration as we started our own search. Using TipRanks, which assembles a comprehensive database of stock performance information, we were able to take a closer look at 3 of the firm’s top picks for 2020. To top it off, each has the support of the rest of the Street as well, boasting a “Strong Buy” consensus rating.Alexion Pharmaceuticals (ALXN)Alexion is best known for developing innovative therapies to improve the lives of patients battling rare diseases. While the company stumbled a bit in 2019 as a result of concerns about competition from biosimilars, Cowen thinks that 2020 could see a major turnaround for the company.Analyst Phil Nadeau tells investors that the market has been “overly harsh” about ALXN’s potential, noting that the shift from its Soliris drug to Ultomiris should bode well for the company. “Our DCF analysis suggests that the current stock price assumes that worldwide sales of ALXN’s C5 franchise in atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH) in 2024 and after are 75% below our current projections. We think that this is an overly pessimistic view of its sustainability. Based on Ultomiris' benefits over Soliris we think that ALXN's franchise is far more defensible than most investors give it credit,” he explained.According to Nadeau, the fact that ALXN has made significant progress in terms of rebuilding its pipeline and transferring the C5 franchise to Ultomiris could drive a re-rating for the healthcare name. Not only does Ultomiris offer improved potency and convenience, but it also has a lower annual price. Additionally, the maturation of its pipeline could contribute to gains in 2020.As a result, the five-star analyst left the Outperform rating and $165 price target as is. At this target, shares could climb 55% in the twelve months ahead. (To watch Nadeau’s track record, click here)What does the rest of the Street have to say? As it turns out, Wall Street is also in favor of ALXN. 12 Buy ratings and 3 Holds received in the last three months make it a Strong Buy. While lower than Nadeau’s estimate, the $145.67 average price target puts the upside potential at a respectable 37%. (See Alexion stock analysis on TipRanks)Alnylam Pharmaceuticals (ALNY)Using RNA interference (RNAi), Alnylam is changing the way debilitating diseases are treated. Based on the Nobel Prize-winning science, the company offers five late-stage programs that could address the large unmet need. Even with shares up 58% in the last year, Cowen’s Ritu Baral believes even more gains are in store.The analyst cites ALNY’s patented GalNAc construct science as well as its clinical strategy as helping it become a “dominant” player in the space. Its ONPATTRO (patisiran) drug for hATTR familial amyloid polyneuropathy (FAP) has already impressed with its performance and has seen consistent growth since its initial launch. In its third quarter, sales came in at $46.1 million, up 21% quarter-over-quarter with 600 patients currently using the therapy. Part of this success is thanks to its partnerships with 23andMe and genetic testing through the Alnylam Act Program, which has increased physician education, disease awareness and helped improve diagnostic methodology.The good news doesn’t stop there in Baral’s opinion. “The company is further de-risked by its late-stage compounds including just-launched GIVLAARI, inclisiran, and lumasiran that should significantly increase recurrent revenues within the next 24-months and drive top-line growth. This is coupled with multiple early stage programs (most wholly owned, some partnered) in both orphan disorders and more prevalent diseases which should yield multiple catalysts in the same time frame,” the five-star analyst commented.Baral argues that the company is transitioning to a “self-sustainable large cap biotechnology”, with this potentially attracting a broader group of investors. It’s no wonder, then, that the analyst boosted the price target from $120 to $154 in addition to maintaining the Outperform rating. This conveys her confidence in ALNY’s ability to surge 33% in the next twelve months. (To watch Baral’s track record, click here)Similarly, the rest of the Street takes a bullish approach when it comes to ALNY. A Strong Buy consensus rating is broken down into 13 Buys, 1 Hold and 1 Sell. Based on the average price target of $136.47, the upside potential lands at 18%. (See Alnylam stock analysis on TipRanks)Argenx SE (ARGX)With a novel approach that combines the diversity of the llama immune system and antibody engineering, Argenx develops treatments for cancer and severe autoimmune diseases. On the heels of a stellar 2019, Cowen is expecting a similar performance to be slated for 2020.Analyst Yaron Werber highlights the company’s lead candidate efgartigimod (anti-FcRn antibody fragment) as having a “potentially best-in-class profile with a first mover advantage across several indications.” The drug is targeting lucrative multi-billion dollar markets, with his estimate putting peak sales at $2.3 billion.While there are treatment options currently available for autoimmune disorders like Myasthenia Gravis (MG), pemphigus vulgaris (PV), idiopathic thrombocytopenic purpura (ITP) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) such as steroids and immunosuppressants, they aren’t always tolerated well and IVIg is expensive, inconvenient and faces capacity constraints. “Efgartigimod is the most advanced FcRn antagonist in development and we anticipate that positive data in PV (POC Ph2: H1:20) and MG (Ph3: H2:20) should drive stock appreciation,” Werber noted.In addition, the company has partnered with Johnson & Johnson, which could speed up the development of cusatuzumab, its anti-CD70 antibody currently in Phase 2.Werber added, “With a deep pipeline, multiple catalysts in FY20 and clear path for near- and longer-term value creation, the stock has ample room for appreciation based on data readouts, derisking clinical milestones, and boosting confidence in new indications.” To this end, Werber reiterated the Outperform rating while also attaching a new $191 price target. Should the five-star analyst’s target be met, shares are looking at a twelve-month gain of 20%. (To watch Werber’s track record, click here)In general, other Wall Street analysts are on the same page. With 10 Buys compared to a single Hold, the word on the Street is that ARGX is a Strong Buy. Given the $180.90 average price target, the upside potential amounts to 14%. (See Argenx stock analysis on TipRanks)
- 01/07/2020
|
Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus
- Biotech stocks advanced in the penultimate week of the year, and the iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) is on track to end the year with gains in excess of 25%. The previous week saw FDA ...
- 12/30/2019
|
Hedge Funds Are Warming Up To argenx SE (ARGX)
- Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 of 2018 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat […]
- 12/07/2019
|
3 “Strong Buy” Biotech Stocks to Watch After Stifel Healthcare Conference
- Are you prone to sudden surges of joy, abruptly followed by sinking bouts of misery? Do you react disproportionately to good or bad news? Well then, you might just be a biotech stock.Known for extreme volatility, biotech stocks can be great news for the risk tolerant investor, but of course, the flipside means they can be bad news, too. So, in this tricky sector, it is hard to know how to choose the right stock to invest in.At Stifel’s recent Healthcare Conference in New York, the investment banking firm took a deep look at some of the biotechs' latest developments. Following the conference’s close, we decided to get the magnifying glass out, and with the help of TipRanks’ Stock Screener home in on the biotech stocks Stifel singled out, but in particular, ones with a Strong Buy consensus rating. Let's dive in.CymaBay Therapeutics (CBAY)First up is CymaBay Therapeutics, a company on a mission to improve the lives of patients with liver and other chronic diseases. The biopharma focuses on developing innovative therapies for patients with rare conditions in which the lack of a market doesn’t cater to their medical needs. These are known as orphan diseases.The company’s main drug is Seladelpar, currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH).As if to prove our introduction regarding biotechs’ volatility, CymaBay lost over 50% in one day in June, following mixed results from the company’s Phase 2b study in NASH, which exhibited minimal reductions in liver fat compared to placebo. Since then the stock has yet to regain a foothold on the market ladder.Stifel’s analyst Derek Archila sat down with CymaBay management, and got the lowdown from the team regarding the Seladelpar trials. The analyst noted, “On the commercial front, management highlighted the potential of seladelpar as part of a combo therapy, with already approved therapies such as the GLP-1R agonists of SGLT2s, given NASH is a multi-factorial disease. We agree with this and see combination therapies playing a key role in treating NASH patients.” Archila further added, “Although NASH is important to the CBAY story, management indicated they view the company as an orphan disease company given seldelpar development is furthest along in PBC, with the Phase 3 ENHANCE study recently completing enrollment. We believe seladelpar has demonstrated sufficient proof-of-concept in this indication.” CymaBay remains on track to report topline data from ENHANCE 52-week study in early 2021.Reassured by the meeting, Archila reiterated his Buy rating on CBAY along with a price target of $14. With CBAY currently trading at $5.61, this indicates substantial upside potential of 150%. (To watch Archila’s track record, click here)It seems like the Street is with Archila on this one. With 3 Buys and 1 Hold the biotech stock has Strong Buy pasted across its label. Importantly, CBAY has an average price target of $14.25, an even slightly more bullish outcome than Archila’s target. (See CymaBay stock analysis on TipRanks)Heron Therapeutics (HRTX)Next up is Heron Therapeutics, a biotech developing treatments for patients suffering from cancer or postoperative pain.The company experienced what we shall call a “biotech classic” in May, when it lost roughly 30% of its value following an FDA rejection of its experimental post-operative pain medication, HTX-011. The rejection centered around the lack of Chemistry, Manufacturing and Controls (CMC) data and was not based on clinical or safety issues.Things are looking up though. In October the FDA accepted Heron’s NDA resubmission for HTX-011 with a PDUFA date set for March 26, 2020. The company is expecting approval and is gearing up to launch HTX-011 shortly thereafter.Stifel’s Derek Archila recently met up with Heron’s CEO Barry Quart, who told Archila: "2020 will be a big year for the company."The analyst noted, “The key point the CEO emphasized is that HRTX's chemo-induced nausea and vomiting (CINV) franchise (Cinvanti and Sustol) is an excellent platform to leverage for the launch of HTX-011 because the target hospitals are very similar. The strategy and tailwinds behind the launch of Cinvanti, such as improved product profile and favorable reimbursement, have produced 42% market share in a market that was 100% controlled by MRK's Emend. Similarly, management believes HTX-011 has an improved profile compared to both generic bupivacaine and PCRX's Exparel both in terms of efficacy and usability.”To this end, Archila reiterated a Buy rating on HRTX stock alongside a $36 price target, indicating an increase of 45% from the recent share price.There’s further good news for HRTX, as currently TipRanks gives Heron a Strong Buy consensus rating. This breaks down into a unanimous 7 "buy" ratings. With an average stock-price forecast of $45.86, the street is in even more of a bullish mood than Archila, providing ample upside of 86% from current levels. (See Heron stock analysis on TipRanks)Argenx (ARGX)Completing our trio of biotechs is the Netherlands’ based Argenx. In a similar vein to both our previous choices, the biopharma focuses on patients with unmet medical needs. Its modus operandi is the development of antibody-based therapies for the treatment of severe auto-immune diseases and cancer.Argenx’s lead drug candidate is efgartigimod, a treatment for patients with severe autoimmune disorders associated with high levels of pathogenic immunoglobulin G, or IgG. Argenx has high hopes for the drug and believes it can have a wide therapeutic impact. It is currently being investigated in MG (myasthenia gravis - a neuro muscular disease), immune thrombocytopenia (a shortage of blood cell fragments needed for normal blood clotting) and skin blistering diseases.At Stifel’s recent Healthcare Conference, Derek Archila sat down with Argenx CEO Tim Van Hauwermeiren for a fire side chat regarding efgartigimod’s progress. The analyst noted, "The first indication it will likely be approved for is MG, for which ARGX expects Phase 3 ADAPT data in 2H20. Management has guided to a potential launch in 2021 for MG. Briefly on the launch, management expects efgartigimod to be used early in the treatment algorithm, after corticosteroids. Efgartigimod will be launched as an IV infusion but has plans to bring a SC form to market in MG.”As a result, Archila reiterated a Buy rating on ARGX along with a price target of $154, implying about 10% upside for the stock.All in all, the rest of the Street has an optimistic view of ARGX. The stock’s Strong Buy status comes from the 7 "buy" and 2 "hold" ratings issued over the previous three months. The upside potential lands at 11%, slightly above Archila's forecast. (See Argenx stock analysis on TipRanks)
- 11/22/2019
|
The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 20) Abbott Laboratories (NYSE: ABT ) ANI Pharmaceuticals Inc Common Stock (NASDAQ: ANIP ) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ) Celgene Corporation (NASDAQ: CELG ) Coherus Biosciences Inc (NASDAQ: CHRS ) DiaMedica Therapeutics Inc (NASDAQ: DMAC )( reported positive interim results from a Phase 1b study of its DM199, which is being evaluated for moderate-to-severe chronic kidney disease) Edesa Biotech Inc (NASDAQ: EDSA )(FDA gave the go ahead to start a Phase 2b trial for EB01, its lead candidate being evaluated for chronic allergic contact dermatitis) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Hologic, Inc. (NASDAQ: HOLX ) Repligen Corporation (NASDAQ: RGEN ) ResMed Inc. (NYSE: RMD ) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 20) Abeona Therapeutics Inc (NASDAQ: ABEO ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) AMAG Pharmaceuticals, Inc.
- 06/21/2019
|
